Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 3 | BMC Research Notes

Figure 3

From: Statin cost effectiveness in primary prevention: A systematic review of the recent cost-effectiveness literature in the United States

Figure 3

Cost-effectiveness ratios for patients at specific risk levels. Incremental cost-effectiveness ratios, shown on the y-axis, were extracted from each article and grouped by 10-year Framingham cardiac risk levels. Within each risk level, the cost-effectiveness of statin treatment was compared with the presumed annual price of statin drugs from each study. Linear regression analysis using Excel spreadsheet function is also shown. QALY, quality adjusted life year; LYG, life year gained.

Back to article page